Report Name: AstraZeneca. Company Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation
AstraZeneca. Company Report – Publisher: Research Cosmos
Price Scheme of the Report:
Single User License – USD 150
Team License – USD 175
Corporate License – USD 250
AstraZeneca. – Business Description:
AstraZeneca (or ‘the company’) is focused on the discovery, development, manufacturing and marketing of prescription pharmaceuticals and biological products in the therapeutics areas of cardiovascular, gastrointestinal, infection, neuroscience, oncology and respiratory. The company operates in the Americas, Europe, Asia and other regions of the world. Astrazeneca has one business segment: biopharmaceuticals. It focuses in various therapeutic areas, namely, cardiovascular (CV) and metabolic; oncology; respiratory, inflammation and autoimmunity; infection, neuroscience and gastrointestinal; and other. The company’s CV products include Crestor (rosuvastatin calcium), Atacand/Atacand HCT/Atacand Plus (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate); Plendil (felodipine); Zestril (lisinopril dihydrate); Axanum (acetylsalicylic acid and esomeprazole); Brilinta/Brilique (ticagrelor); Tenormin (atenolol); and Zestril (lisinopril dihydrate). AstraZeneca’s metabolic products are Byetta (exenatide injection) and Bydureon (exenatide extended release injectable suspension); Bydureon Pen (exenatide extended-release for injectable suspension); Forxiga/Farxiga (dapagliflozin); Kombiglyze XR (saxagliptin and metformin XR); Komboglyze (saxagliptin and metformin HCl); Onglyza (saxagliptin); Symlin (pramlintide acetate); Xigduo (dapagliflozin and metformin hydrochloride); Xigduo XR (dapagliflozin and metformin hydrochloride extended-release); and Myalept (metreleptin for injection). The company’s oncology products include Arimidex (anastrozole); Faslodex (fulvestrant); Casodex (bicalutamide); Zoladex (goserelin acetate implant); Iressa (gefitinib); Nolvadex (tamoxifen citrate); Caprelsa (vandetanib); and Lynparza (olaparib). In the respiratory, inflammation and autoimmunity therapeutic area, the company markets the following products for the treatment of chronic obstructive pulmonary disease (COPD) and/or asthma: Bricanyl Turbuhaler (terbutaline in a dry powder inhaler) Symbicort pMDI (budesonide/formoterol in a pressurised metered-dose inhaler), Pulmicort Turbuhaler (budesonide in a dry powder inhaler), Pulmicort Respules (budesonide inhalation suspension), Oxis Turbuhaler (formoterol in a dry powder inhaler) and Accolate (zafirlukast), Duaklir Genuair (aclidinium/formoterol), Eklira Genuair /Tudorza/Bretaris (aclidinium, a LAMA). The company also offers Rhinocort (budesonide), a nasal steroid treatment for allergic rhinitis (hay fever), perennial rhinitis and nasal polyps. AstraZeneca’s gastrointestinal products include Prilosec (omeprazole; Losec outside the US), Nexium (esomeprazole); and Entocort (budesonide). In the neuroscience therapeutic area, AstraZeneca offers psychiatry products, Seroquel IR (an immediate release formulation of quetiapine fumarate); Seroquel XR (an extended release formulation of quetiapine fumarate); Diprivan (propofol); EMLA (lidocaine and prilocaine); Naropin (ropivacaine); Vimovo (naproxen/esomeprazole magnesium); Xylocaine (lidocaine); and Zomig (zolmitriptan). In the infection and other therapeutic area, the company offers Synagis (palivizumab); Cubicin (daptomycin), Merrem/Meronem (meropenem) and Zinforo (ceftaroline fosamil). The company also offers influenza vaccines, FluMist/Fluenz and FluMist Quadrivalent/Fluenz Tetra.
Scope of the Report:
About the Company: Historical Details, Current Ownership Structure and basic overview of AstraZeneca. in terms of revenue, net income, and operating income.
Financials: Details about AstraZeneca. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.
Company SWOT Analysis: Outlines AstraZeneca.’s strengths, weaknesses, and opportunities and threats facing the company.
Recent Developments: Showcases AstraZeneca.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
Strategic Evaluation: This section provides an overview of AstraZeneca.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.
Key Questions Answered
What domain does AstraZeneca. operate and what are key points about it?
What is the product/service portfolio of AstraZeneca.?
How has AstraZeneca. performed financially from 2013?
How does AstraZeneca. rank among its peers in terms of revenue and market share?
What are AstraZeneca. strengths and weaknesses and what opportunities and threats do it face?
What are AstraZeneca.’s main growth strategies and how successful has the company been at implementing them?
What is the in-house technical capability of AstraZeneca.? Where does it procure/outsource it?
Reasons to buy
Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost
12 hour delivery time fulfilling your urgent requests as per your requirement
On-demand customization options that can completely cater to your needs by focusing the report on given specifics
For More Information, Get Sample of the report:Request Sample
Got Some Questions? Inquire Here:Inquire Before Buying
Get This Report:Purchase Now
For More Details, Contact Provider Directly:
Kevin Stewart
Sales Manager
Research Cosmos
[email protected]
+1 888 709 8757
The post AstraZeneca. Overview, AstraZeneca. Company Profile, AstraZeneca. SWOT Analysis appeared first on Market Reports Web.
